Status:
UNKNOWN
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Lead Sponsor:
Robert Negrin
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Multiple Myeloma
Blood and Marrow Transplant (BMT)
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to determine if the use of activated T cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing GVHD.
Eligibility Criteria
Inclusion
- Evidence of recurrent or persistent hematologic malignancy following HLA matched allogeneic hematopoietic cell transplant
- eligible for DLI
- no evidence of GVHD
- stable immunosuppressive regimen
- adequate renal and liver function
Exclusion
- CML patients who have not received DLI, active infections
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00185757
Start Date
June 1 2004
End Date
December 1 2012
Last Update
December 17 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305